Hot Flash Pills
vs
Vaginal Dryness Pills

A side-by-side comparison of two menopause relief methods — efficacy, cost, how they work, and who shouldn't use them.

Side-by-side comparison

Method
Hot Flash Pills

Hot Flash Pills

A daily prescription pill (neurokinin receptor antagonist) that blocks NK3 receptors in the brain to reduce hot flashes and night sweats.
Vaginal Dryness Pills

Vaginal Dryness Pills

SERM prescription pills that act like estrogen in some tissues and block it in others to relieve vaginal dryness and painful sex.
EfficacyRecommended see details

Recommended by the Menopause Society for symptom relief.

68.3% had symptom improvement

Around 68% had symptom improvement.

Cost$0–$780 /monthly

Insurance: Usually

$0–$340 /monthly

Insurance: Usually

DurationDaily pill (ongoing)Daily pill (ongoing)
ReversibilityReversibleReversible
STI ProtectionNoNo
How it works

Blocks neurokinin-3 (NK3) and/or neurokinin-1 (NK1) receptors in the hypothalamus to interrupt the temperature-regulation pathway that triggers hot flashes and night sweats.

SERMs bind to estrogen receptors and act like estrogen in some tissues (bone, vagina) while blocking estrogen in others (breast, uterus). This tissue-selective action can treat menopause symptoms without systemic estrogen.

PrescriptionRequired Prescription requiredRequired Prescription required
Available Products2 products1 product
Side effects
  • Elevated liver enzymes (requires monitoring)
  • Abdominal pain
  • Diarrhea
  • Insomnia
  • Back pain
  • Hot flush
  • Headache
  • Somnolence, dizziness, and fatigue (more common with dual NK1/NK3 antagonists)
  • Hot flashes (paradoxical in some users)
  • Vaginal discharge
  • Muscle spasms
  • Hyperhidrosis
  • Headache
  • Vaginal hemorrhage
  • Night sweats
Who shouldn't use this
  • Cirrhosis or severe liver disease (NK3 antagonists such as fezolinetant)
  • Severe renal impairment or end-stage renal disease (NK3 antagonists such as fezolinetant)
  • Concomitant use of CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin (NK3 antagonists such as fezolinetant)
  • Pregnancy (dual NK1/NK3 antagonists such as elinzanetant)
  • Known or suspected estrogen-dependent neoplasia (e.g., breast or endometrial cancer)
  • Active DVT, pulmonary embolism, or a history of these conditions
  • Active arterial thromboembolic disease (e.g., stroke, myocardial infarction) or a history of these conditions
  • Undiagnosed abnormal genital bleeding
  • Known or suspected pregnancy
  • Hypersensitivity to ospemifene or any ingredient